Mega%2525252525252525252525252525252525252520cv

# Mega CV > **Identification note:** “Mega%2525…cv” appears to be repeatedly URL-encoded. This response assumes **Mega CV refers to amoxicillin/clavulanate (co-amoxiclav)**. Confirm the active ingredients and strength on the package before prescribing; brand formulations vary by country. ## Overview Amoxicillin/clavulanate is an oral aminopenicillin plus a β-lactamase inhibitor. Doses are expressed by the **amoxicillin component**, with the clavulanate amount shown separately. - Common immediate-release strengths: **250/125 mg, 500/125 mg, 875/125 mg** - Extended-release products have different dosing and should not be substituted mg-for-mg. - Take **at the start of a meal** to improve gastrointestinal tolerability and clavulanate absorption. - Not effective for viral infections. ## Primary Indications Treatment of susceptible bacterial infections, including: - Acute bacterial sinusitis - Acute otitis media - Lower respiratory tract infections - Skin and soft-tissue infections - Dental/odontogenic infections - Urinary tract infections - Animal or human bite wounds Use should follow local resistance patterns and culture results when available. ## Adult Dosing For immediate-release oral products: - **Mild to moderate infection:** 500/125 mg orally every 12 hours or 250/125 mg every 8 hours. - **Severe infection or respiratory infection:** 875/125 mg every 12 hours or 500/125 mg every 8 hours. - **Typical duration:** 5–7 days; commonly 5–10 days depending on infection and clinical response. Avoid prolonged courses without reassessment. - **Maximum commonly used immediate-release dose:** amoxicillin 4 g/day; do not exceed the labeled clavulanate exposure. For the specific extended-release 2000/125 mg formulation, dosing is commonly **2 tablets every 12 hours** for selected adult respiratory infections, but this product has formulation-specific indications and should not be substituted for standard tablets. ## Pediatric Dosing Dose using the **amoxicillin component**. ### Children ≥3 months and weighing <40 kg - **Mild to moderate infection:** 25 mg/kg/day divided every 12 hours, or 20 mg/kg/day divided every 8 hours. - **Severe infection, otitis media, sinusitis, or lower respiratory infection:** 45 mg/kg/day divided every 12 hours, or 40 mg/kg/day divided every 8 hours. - **High-dose regimen when indicated:** 80–90 mg/kg/day divided every 12 hours; use a formulation designed to limit clavulanate exposure. - **Maximum:** generally amoxicillin 4 g/day in older/larger children; product-specific pediatric maximums apply. ### Infants <3 months - **30 mg/kg/day of amoxicillin divided every 12 hours** using an appropriate pediatric formulation. ### Children ≥40 kg Use adult dosing. Pediatric suspension concentrations are not interchangeable; calculate the volume from the labeled concentration. ## Dose Adjustments ### Renal impairment in adults Adjust according to creatinine clearance (CrCl), using immediate-release formulations: - **CrCl >30 mL/min:** no adjustment generally required. - **CrCl 10–30 mL/min:** 250/125 mg or 500/125 mg every 12 hours; avoid 875/125 mg. - **CrCl <10 mL/min:** 250/125 mg or 500/125 mg every 24 hours; avoid 875/125 mg. - **Hemodialysis:** dose every 24 hours with an additional dose during or after dialysis per local protocol. Pediatric renal dosing is product- and age-dependent; consult a pediatric dosing reference. ### Hepatic impairment - No standard dose reduction is established. - Use cautiously in significant hepatic disease. - Avoid if previous amoxicillin/clavulanate-associated cholestatic jaundice or hepatic dysfunction occurred. - Monitor liver function during prolonged therapy or in patients with liver disease. ## Contraindications - Previous serious immediate or delayed hypersensitivity reaction to amoxicillin, penicillins, cephalosporins, or other β-lactams - Previous amoxicillin/clavulanate-associated cholestatic jaundice or hepatic dysfunction - Do not use when the infection is likely viral, including uncomplicated viral upper respiratory infection ## Adverse Effects Common: - Diarrhea, nausea, vomiting - Abdominal discomfort - Rash - Vulvovaginal candidiasis or oral candidiasis Serious: - Anaphylaxis, angioedema, bronchospasm - Severe cutaneous reactions, including Stevens–Johnson syndrome and DRESS - *Clostridioides difficile*-associated diarrhea or colitis - Cholestatic hepatitis or liver injury - Hemolytic anemia, thrombocytopenia, leukopenia, or seizures, usually with severe renal impairment or excessive exposure Stop and urgently evaluate severe rash, facial swelling, breathing difficulty, jaundice, or persistent/watery/bloody diarrhea. ## Key Drug Interactions - **Warfarin and other anticoagulants:** may increase INR; monitor INR and bleeding. - **Methotrexate:** may increase methotrexate toxicity; monitor closely or avoid when possible. - **Probenecid:** increases and prolongs amoxicillin concentrations; generally avoid routine coadministration. - **Allopurinol:** may increase rash risk. - **Oral hormonal contraceptives:** clinically significant reduction is not well established, but advise backup contraception if vomiting or severe diarrhea occurs. - **Live bacterial vaccines, especially oral typhoid:** antibiotics may reduce vaccine effectiveness; separate administration according to vaccine guidance. ## Monitoring - Clinical response within 48–72 hours - Allergy, rash, and signs of anaphylaxis - Diarrhea, particularly severe or persistent diarrhea - Renal function when treatment is prolonged, the patient is elderly, or renal impairment is present - Liver function with prolonged therapy, baseline liver disease, or symptoms of hepatotoxicity - INR in patients receiving warfarin - Appropriate cultures and susceptibility testing for serious, recurrent, or treatment-resistant infections ## Clinical Pearls - Verify the **exact formulation and strength**; amoxicillin/clavulanate products are not interchangeable. - Prescribe using the **lowest effective clavulanate exposure** to reduce diarrhea. - Pediatric high-dose therapy should use an appropriate high-amoxicillin/low-clavulanate formulation. - Do not use the 875/125 mg tablet in patients with **CrCl ≤30 mL/min**. - Complete the prescribed course, but reassess if symptoms worsen or fail to improve within 48–72 hours. - Suspension should be shaken well, measured with an oral syringe, refrigerated when required by the product label, and discarded according to manufacturer instructions. - If “Mega CV” contains an ingredient other than amoxicillin/clavulanate, these recommendations may be incorrect. *Educational information only; verify the active ingredients, formulation, local dosing protocol, renal recommendations, and current prescribing information before use.*